Baker BROS. Advisors LP Grows Position in Entrada Therapeutics, Inc. $TRDA

Baker BROS. Advisors LP increased its position in shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) by 4.3% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 5,072,730 shares of the company’s stock after buying an additional 206,911 shares during the period. Baker BROS. Advisors LP owned about 0.13% of Entrada Therapeutics worth $52,148,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in the company. Allspring Global Investments Holdings LLC increased its stake in shares of Entrada Therapeutics by 9.8% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 17,495 shares of the company’s stock worth $176,000 after buying an additional 1,560 shares during the period. Alliancebernstein L.P. boosted its position in shares of Entrada Therapeutics by 7.1% during the 3rd quarter. Alliancebernstein L.P. now owns 24,320 shares of the company’s stock worth $141,000 after acquiring an additional 1,620 shares in the last quarter. Great Lakes Advisors LLC boosted its position in shares of Entrada Therapeutics by 5.5% during the 4th quarter. Great Lakes Advisors LLC now owns 43,268 shares of the company’s stock worth $445,000 after acquiring an additional 2,239 shares in the last quarter. First Trust Advisors LP boosted its position in shares of Entrada Therapeutics by 3.6% during the 2nd quarter. First Trust Advisors LP now owns 75,120 shares of the company’s stock worth $505,000 after acquiring an additional 2,631 shares in the last quarter. Finally, Russell Investments Group Ltd. boosted its position in shares of Entrada Therapeutics by 31.4% during the 4th quarter. Russell Investments Group Ltd. now owns 11,571 shares of the company’s stock worth $119,000 after acquiring an additional 2,763 shares in the last quarter. 86.39% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts have recently issued reports on the company. HC Wainwright cut Entrada Therapeutics from a “buy” rating to a “neutral” rating in a research report on Friday, May 8th. Cantor Fitzgerald assumed coverage on Entrada Therapeutics in a research report on Wednesday, April 1st. They set an “overweight” rating for the company. Wall Street Zen cut Entrada Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 28th. Weiss Ratings cut Entrada Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research report on Thursday, June 11th. Finally, Guggenheim lowered their price objective on Entrada Therapeutics from $20.00 to $17.00 and set a “buy” rating for the company in a research report on Monday, June 8th. Three investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Entrada Therapeutics has a consensus rating of “Hold” and an average target price of $17.50.

Insider Buying and Selling at Entrada Therapeutics

In other Entrada Therapeutics news, Director Bernhardt G. Zeiher bought 5,000 shares of the business’s stock in a transaction dated Wednesday, May 20th. The shares were acquired at an average cost of $5.86 per share, with a total value of $29,300.00. Following the acquisition, the director directly owned 5,000 shares of the company’s stock, valued at $29,300. The trade was a ? increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Natarajan Sethuraman sold 25,907 shares of Entrada Therapeutics stock in a transaction on Monday, May 4th. The shares were sold at an average price of $15.39, for a total transaction of $398,708.73. Following the completion of the transaction, the insider directly owned 216,317 shares in the company, valued at $3,329,118.63. The trade was a 10.70% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 43,407 shares of company stock valued at $661,034. Insiders own 9.49% of the company’s stock.

Entrada Therapeutics Price Performance

Shares of TRDA opened at $6.81 on Thursday. Entrada Therapeutics, Inc. has a 1-year low of $4.93 and a 1-year high of $16.45. The stock has a market cap of $264.36 million, a PE ratio of -1.71 and a beta of -0.26. The firm has a fifty day moving average price of $9.43 and a 200 day moving average price of $10.63.

Entrada Therapeutics (NASDAQ:TRDA) last announced its earnings results on Thursday, May 7th. The company reported ($0.95) EPS for the quarter, beating analysts’ consensus estimates of ($1.06) by $0.11. The business had revenue of $0.88 million for the quarter, compared to analysts’ expectations of $2.92 million. Entrada Therapeutics had a negative net margin of 2,895.05% and a negative return on equity of 51.22%. As a group, equities analysts expect that Entrada Therapeutics, Inc. will post -4.12 EPS for the current fiscal year.

Entrada Therapeutics Profile

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.